Therapeutic Cancer Vaccines Treatments Market 2019

GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 – Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake”. There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬–resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patient survival, some by a few months, others by years. The high anticipated price tag of these vaccines will be a barrier of market growth. However, due to the fact that numerous vaccines are anticipated to be approved across a range of highly diagnosed indications, GBI Research believes the global market does have the potential to grow to a value of $7.8 billion by 2019.

Scope

- The report analyzes treatment usage patterns, variation in vaccine type and pipeline and market forecasts across indications for cancer vaccines.

- A brief introduction into cancer, its relation with the immune system, and a detailed outline of the 8 different types of cancer vaccines being developed, including their strengths and weaknesses.

- An analysis of Provenge, the only currently marketed therapeutic cancer vaccines, including recent sales figures and potential future competitors of Provenge.

- Comprehensive reviews of the pipeline for therapeutic cancer vaccines with individual analyses on the most heavily researched and most common cancers of melanoma, breast, prostate, colorectal, stomach and Non-small-cell lung cancer. The analyses include the phase distribution, the most common type of vaccine and most frequently observed molecular target for each indication.

- A statistical analysis of clinical trial duration and size by phase and by vaccine type.

- An in depth forecast model for each indication for which a vaccine is anticipated to be approved throughout the forecast period. Each model is based on the anticipated market performance of the vaccines to be approved for that indication.

- A detailed discussion of the drivers and barriers for this novel market.

Get a Report Copy @ http://www.rnrmarketresearch.com/therapeutic-cancer-vaccines-market-to-2019-pipeline-indicates-safer-treatments-and-extended-patient-survival-though-high-prices-may-limit-uptake-market-report.html

Reasons To Buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Understand the variation in the types of therapeutic cancer vaccines, and the strength and weaknesses of each form.

- Understand the vast scope of the pipeline, including which vaccine types and molecular targets are generating the most interest.

- Observe the trends in clinical trial duration and size amongst Phases and vaccine types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for therapeutic cancer vaccines.

- Observe the shift in clinical trial endpoints with Phase, and use this data to potentially influence any future developmental programs.

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the therapeutic cancer vaccines market.

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=89452

Table of Content

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Cancer Epidemiology 11
2.2 Disease Initiation and Propagation 11
2.3 Symptoms 12
2.3.1 Symptoms of Lung Cancer 12
2.3.2 Symptoms of Prostate Cancer 12
2.3.3 Symptoms of Colorectal Cancer 12
2.3.4 Symptoms of Breast Cancer 12
2.3.5 Symptoms of Melanoma 12
2.3.6 Symptoms of Stomach Cancer 12
2.4 Current Treatment and Management 13
2.4.1 Active Surveillance or the ‘Wait-and See’ Approach 13
2.4.2 Surgery 13
2.4.3 Radiation Therapy 13
2.4.4 Chemotherapy 13
2.4.5 Targeted Therapy 13
2.4.6 Hormone Therapy 14
2.4.7 Immunotherapy 14
2.5 Virally Induced Cancers and Prophylactic Vaccines 14
2.6 Cancer, the Immune system and Therapeutic Vaccines 15
2.6.1 Mechanisms of Immune System Evasion 15
2.6.2 Mechanisms of Immune System Disabling 15
2.7 Why Develop Therapeutic Cancer Vaccines? 16
2.8 Types of Therapeutic Cancer Vaccine 16
2.8.1 Anti-Idiotype Vaccines 16
2.8.2 Whole-Cell-Derived Vaccines 16
2.8.3 Cellular Immunotherapy 17
2.8.4 Antigen-Based Vaccines 17
2.8.5 DNA-Based Vaccines 17
2.8.6 Vector-Based (Microorganism-Facilitated) Vaccines 17
2.8.7 Oncolytic Virus Vaccines 18
2.8.8 Adjuvants 18

3 Marketed Products 19
3.1 Provenge – an Autologous Cellular Immunotherapy Vaccine for the Treatment of Hormone-Refractory Prostate Cancer 19
3.1.1 Overview 19
3.1.2 Mechanism of Action and Molecular Target 19
3.1.3 Formulation and Dosing 19
3.1.4 Provenge within the Clinical Landscape for Prostate Cancer 19
3.1.5 Company Profile and Patent Expiry 20
3.2 Recent Sales and Commercialization of Provenge 20
3.3 Current and Future Market Competitors for Provenge 22

4 Product Pipeline 24
4.1 Pipeline Overview 24
4.1.1 Developmental Pipeline of all Major Indications 27
4.1.2 Clinical Trials 36
4.1.3 Clinical Trial Failure 41
4.1.4 Key Companies Developing Cancer Vaccines 44
4.1.5 Promising Drugs in the Developmental Pipeline 45

5 Forecasting 52
5.1 Therapeutic Cancer Vaccines Market to 2019 – Global 52
5.1.1 Treatment Usage Patterns 53
5.1.2 Annual Cost of Treatment 53
5.2 Colorectal Cancer 53
5.2.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns 53
5.2.2 Annual Cost of Therapy 54
5.2.3 Market Size 56
5.3 Glioblastoma Multiforme 58
5.3.1 Emerging Cancer Vaccines and their Treatment Usage Patterns 58
5.3.2 Annual Cost of Therapy 59
5.3.3 Market Size 60
5.4 Lymphoma 62
5.4.1 Emerging Cancer Vaccines for Lymphoma and their Treatment Usage Patterns 62
5.4.2 Annual Cost of Therapy 62
5.4.3 Market Revenues 64
5.5 Melanoma 66
5.5.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns 66
5.5.2 Annual Cost of Therapy 67
5.5.3 Market Size 69
5.6 Non-Small-Cell Lung Cancer 71
5.6.1 Emerging Vaccines and Treatment Usage Patterns 71
5.6.2 Annual Cost of Therapy 71
5.6.3 Market Size 73
5.7 Pancreatic Cancer 74
5.7.1 Emerging Cancer Vaccines and their Market Impact 74
5.7.2 Annual Cost of Therapy 74
5.7.3 Market Revenues 76
5.8 Prostate Cancer 78
5.8.1 Treatment Usage Patterns and the Impact of Emerging Vaccines 78
5.8.2 Annual Cost of Treatment 78
5.8.3 Market Revenues 80
5.9 Drivers and Barriers for Therapeutic Cancer Vaccines Market 82
5.9.1 Drivers 82
5.9.2 Barriers 83

6 Appendix 85
6.1 Provenge Clinical Trial Titles (Table 3) 85
6.2 Predicated Annual Cost of Therapy 85
6.2.1 Colon Cancer 85
6.2.2 Glioblastoma Multiforme 85
6.2.3 Lymphoma 86
6.2.4 Melanoma 86
6.2.5 Non-Small-Cell Lung Cancer 87
6.2.6 Pancreatic Cancer 87
6.2.7 Prostate Cancer 88
6.3 Predicted Market Forecasts 88
6.3.1 Colon Cancer 88
6.3.2 Glioblastoma Multiforme 89
6.3.3 Lymphoma 89
6.3.4 Melanoma 90
6.3.5 Non-Small-Cell Lung Cancer 90
6.3.6 Pancreatic Cancer 91
6.3.7 Prostate 91
6.4 All Pipeline Drugs by Phase 92
6.4.1 Discovery 92
6.4.2 Preclinical 93
6.4.3 IND-Filed and Phase 0 95
6.4.4 Phase I 96
6.4.5 Phase II 101
6.4.6 Phase III 105
6.5 Market Definitions 106
6.6 Abbreviations 107
6.7 Sources 108
6.8 Research Methodology 111
6.8.1 Coverage 111
6.8.2 Secondary Research 111
6.8.3 Primary Research 112
6.8.4 Therapeutic Landscape 112
6.8.5 Epidemiology-Based Forecasting 112
6.8.6 Analogous Forecasting Methodology 113
6.8.7 Diseased Population 113
6.8.8 Prescription Population 113
6.9 Market Size by Geography 114
6.9.1 Forecasting Model for Therapeutic Areas 114
6.10 Geographical Landscape 115
6.11 Pipeline Analysis 115
6.12 Expert Panel Validation 115
6.13 Contact Us 115
6.14 Disclaimer 115